Why the study?
Does roscovitine suppress oxidative EAD-mediated VT/VF in preclinical models?
Does roscovitine suppress oxidative EAD-mediated VT/VF in preclinical models?
Specific blockers of late inward currents (proposed as Class VI antiarrhythmics) like roscovitine may offer a novel approach to treating VT/VF, particularly in conditions with enhanced CaMKII activity such as heart failure.
without affecting its peak with the prototype drug, roscovitine suppressed oxidative EAD-mediated VT/VF. These findings indicate that specific blockers of the late inward currents without affecting their peaks (gating modifiers), offer a new and effective AAD class action i.e., "Class VI." The development of safe drugs with selective Class VI actions provides a rational and effective approach to treat VT/VF particularly in cardiac conditions associated with enhanced CaMKII activity such as heart failure.
No takes yet. Share an insight, caveat, or question.
Karagueuzian et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: